A couple drops in your eye usually brings relief, not concern—but a rare recall case highlights the importance of a clean, sterile bottle.

The global ophthalmic sprays market, valued at USD 343 million in 2023, is projected to experience exponential growth, ...

Jan. 15, 2025 — Scientists have come up with a drug that is a potential candidate for tackling memory deficits in the early stages of the disease in rodents. ... New Innovative Local Treatment ...

To provide your eyes with a little extra relief, we’ve rounded up some of the top editor-tested and shopper-reviewed under-eye patches that quickly brighten and de-puff and are worthy of any ...

In a phase 3 trial, Tenpoint Therapeutics’ eye drop—a combination of carbachol and brimonidine—improved vision for patients with presbyopia for up to eight hours. The top-line results come f ...

The top vitamins for eye health are essential to keeping them healthy and your vision clear. Eating a balanced diet is the best way to stay healthy, but sometimes, you need a little help to meet ...

ACADIA Pharmaceuticals shareholders are down 43% for the year, but the market itself is up 26%. Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental ...

EyePoint Pharmaceuticals announced the appointment of Dr. Reginald J. Sanders, a renowned retina specialist and leader in ophthalmology, to its Board of Directors. This strategic addition is ...

Fintel reports that on January 7, 2025, Citigroup initiated coverage of EyePoint Pharmaceuticals (NasdaqGM:EYPT) with a Buy recommendation. Analyst Price Forecast Suggests 265.47% Upside As of ...

ACADIA Pharmaceuticals shareholders are down 43% for the year, but the market itself is up 26%. Even the share prices of good stocks drop sometimes, but we want to see improvements in the ...

EyePoint Pharmaceuticals (EYPT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Yigal Nochomovitz from Citi maintained a Buy rating on the ...

Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Vertex Pharmaceuticals. Recent revisions tend to reflect the latest near-term business trends.